Salt Lake City-based healthcare products and services company Spectrum Solutions has acquired Alimetrix Inc., a molecular diagnostic laboratory, and Microarrays Inc., a provider of customer array-based products that are used as biological research tools. The two acquired firms are business associates and based in Huntsville, Alabama.
Spectrum Solutions is a healthcare solutions partner with the announced purpose of bridging the gap between the science and real medical solutions. Its laboratory products and services, clinical testing and onsite compounding pharmacy drive decentralized testing, accelerate scientific applications, modernize direct-to-consumer wellness and deliver innovation with the practical power to impact and change outcomes, the company said.
“These valuable assets, combined with our core competencies of providing industry-leading contract manufacturing services and unique biospecimen collection devices, creates a unique synergistic relationship resulting in a portfolio of products and services that enhances the overall patient testing experience whether in a clinical setting or at home,” Spectrum said in a press statement announcing the acquisitions. “Alimetrix’s molecular laboratory capabilities and Microarrays’ expertise in manufacturing array-based products, now coupled with Spectrum’s capabilities, creates a comprehensive suite of products and services accelerating Spectrum’s go-to-market strategies.”
“The acquisitions of Alimetrix and Microarrays not only enhances Spectrum’s portfolio to include high-impact laboratory testing and custom assay services, it also serves to advance patient care and clinical research,” said Stephen Fanning, CEO of Spectrum Solutions. “Spectrum is now one step closer to its vision of developing a transformative, decentralized healthcare platform aimed at innovating the way biospecimens are collected and laboratory testing is conducted.”
“At Alimetrix and Microarrays, our mission has always been dedicated to performing work bigger than ourselves that enables positive change in the world through science. Joining forces with a scientifically committed company like Spectrum will extend and enhance our capabilities to the masses and help individuals and communities take control of their health,” said Joel Peek, president and chief science officer at Alimetrix and Microarrays.
Financial details of the acquisition were not announced.